Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population

We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a clinical re...

Descripción completa

Detalles Bibliográficos
Autores principales: Bryson-Cahn, Chloe, Beieler, Alison M, Chan, Jeannie D, Harrington, Robert D, Dhanireddy, Shireesha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388764/
https://www.ncbi.nlm.nih.gov/pubmed/30838225
http://dx.doi.org/10.1093/ofid/ofz028
_version_ 1783397813791490048
author Bryson-Cahn, Chloe
Beieler, Alison M
Chan, Jeannie D
Harrington, Robert D
Dhanireddy, Shireesha
author_facet Bryson-Cahn, Chloe
Beieler, Alison M
Chan, Jeannie D
Harrington, Robert D
Dhanireddy, Shireesha
author_sort Bryson-Cahn, Chloe
collection PubMed
description We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a clinical response to treatment. Only 1 patient who completed the intended dalbavancin course experienced a treatment failure.
format Online
Article
Text
id pubmed-6388764
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-63887642019-03-05 Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population Bryson-Cahn, Chloe Beieler, Alison M Chan, Jeannie D Harrington, Robert D Dhanireddy, Shireesha Open Forum Infect Dis Brief Report We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a clinical response to treatment. Only 1 patient who completed the intended dalbavancin course experienced a treatment failure. Oxford University Press 2019-01-30 /pmc/articles/PMC6388764/ /pubmed/30838225 http://dx.doi.org/10.1093/ofid/ofz028 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Bryson-Cahn, Chloe
Beieler, Alison M
Chan, Jeannie D
Harrington, Robert D
Dhanireddy, Shireesha
Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
title Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
title_full Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
title_fullStr Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
title_full_unstemmed Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
title_short Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
title_sort dalbavancin as secondary therapy for serious staphylococcus aureus infections in a vulnerable patient population
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388764/
https://www.ncbi.nlm.nih.gov/pubmed/30838225
http://dx.doi.org/10.1093/ofid/ofz028
work_keys_str_mv AT brysoncahnchloe dalbavancinassecondarytherapyforseriousstaphylococcusaureusinfectionsinavulnerablepatientpopulation
AT beieleralisonm dalbavancinassecondarytherapyforseriousstaphylococcusaureusinfectionsinavulnerablepatientpopulation
AT chanjeannied dalbavancinassecondarytherapyforseriousstaphylococcusaureusinfectionsinavulnerablepatientpopulation
AT harringtonrobertd dalbavancinassecondarytherapyforseriousstaphylococcusaureusinfectionsinavulnerablepatientpopulation
AT dhanireddyshireesha dalbavancinassecondarytherapyforseriousstaphylococcusaureusinfectionsinavulnerablepatientpopulation

Ejemplares similares